Immunomic Therapeutics CEO and leadership

I am experienced bio-entrepreneur and currently CEO of Immunomic Therapeutics, Inc. (\'ITI\') As primary founder of ITI, I worked with my team to guide the Company through its early stages, selected key strategies for deploying our novel technology and negotiated one of the largest upfront cash license deals in biotechnology ($300 million with Astellas Pharma in allergy).

In order to achieve this success, I needed to draw on all of my career experiences:

- as a scientist with excellent communication skills and depth in immunology and molecular biology

- as the senior leader of my team, getting many moving parts to work towards the same goal together

- as a CEO by assembling highly talented people and enabling them to work unencumbered

- as a business development executive and negotiator

- as a business partner, communicating that our company would be an effective team player

The road to that success is a story which is worth sharing with those just starting out or looking at ways to enhance their business successes. I welcome the opportunity to speak with those who want to learn about ITI or the road we traveled to become a biotech success story.

Dr. Teri Heiland is the Chief Scientific Officer at Immunomic Therapeutics and cofounder of the Company. She has over 20 years of senior industry leadership experience. Her primary focus and expertise is in DNA vaccine design, optimization and development. In addition to her work to develop, shape and apply the UNITE technology platform, she has led multiple research teams to develop products and platform technologies. Dr. Heiland is also one of the founders of Capital Genomix, Inc. (CGI), a Maryland-based biomarker and drug discovery Company and served as its VP of Research and Development until 2006.

As a key contributor to the Immunomic executive team, Dr. Heiland plays a critical role in forging and achieving leading new research and development collaborations in order to further improve the UNITE platform and develop new applications for the technology. In 2015, those efforts resulted in an exclusive license valued at over $300 million with Japan-based Astellas for next generation allergy vaccines based on the UNITE platform.

Dr. Heiland is an inventor on multiple patents and was a principal investigator on grants from the Department of Defense and NIAID. She received her Ph.D. in Molecular Immunology and Microbiology at the University of Missouri-Columbia.

Eric Winzer joined OpGen as Chief Financial Officer in June 2009. Eric brings almost 30 years of experience in addressing diverse financial issues including raising capital, financial reporting, investor relations, banking, taxation, mergers and acquisitions, financial planning and analysis, and accounting operations. Eric is responsible for all financial functions at the Company. Prior to joining Opgen, Eric served as Executive Vice President and Chief Financial Officer for Avalon Pharmaceuticals, Inc., a biotechnology company developing targeted therapeutics for oncology. Prior to Avalon, Eric was with Life Technologies Corporation (formerly Invitrogen Corporation), a provider of life science technologies for disease research and drug discovery, where he served as Senior VP and Chief Financial Officer, Executive Sponsor for Life’s ERP implementation, and as the VP of Finance. Previously held positions also include Eric’s tenure at Life Technologies Incorporated, where he assumed increasing responsibility as Chief Financial Officer, Secretary and Treasurer, and additionally held various financial positions at Genex Corporation. Currently, Eric serves as director and audit committee chair at Cytomedix, Inc. Eric received his B.A. in Economics and Business Administration from McDaniel College and an M.B.A. from Mount Saint Mary’s University.

Allan is a highly regarded biopharma executive and board member, who brings 20+ years of extensive senior global strategic, financial, M&A, operational, capital markets and governance experience. Notably, he has led raising more than $4 billion in public/private financings (including two IPOs). Most recently, Mr. Shaw took Syndax Pharmaceuticals, Inc. public as its Chief Financial Officer. Mr. Shaw has also served as the Chief Financial Officer of Serono S.A. (third largest global biotechnology company). He also formerly had a monthly column in Life Science Leader magazine entitled “Deeper Dive - a CFO insider’s view of the issues impacting the industry” and has contributed to several corporate governance books.

Results-driven pharmaceutical/biotech Senior Operations Executive with in-depth drug discovery and development knowledge. Extensive experience managing all stages of program management from preclinical through approval and commercial launch with both small molecule and biologics experience. International experience with demonstrated capabilities interfacing with and representing interests across multi-site corporations and contract organizations as well as smaller virtual organizations. Team builder who recognizes the dramatic difference culture can have on results and organizational harmony. Adept at translating stakeholder interests across all disciplines involved in the drug development process.

I am experienced bio-entrepreneur and currently CEO of Immunomic Therapeutics, Inc. (\'ITI\') As primary founder of ITI, I worked with my team to guide the Company through its early stages, selected key strategies for deploying our novel technology and negotiated one of the largest upfront cash license deals in biotechnology ($300 million with Astellas Pharma in allergy).

In order to achieve this success, I needed to draw on all of my career experiences:

- as a scientist with excellent communication skills and depth in immunology and molecular biology

- as the senior leader of my team, getting many moving parts to work towards the same goal together

- as a CEO by assembling highly talented people and enabling them to work unencumbered

- as a business development executive and negotiator

- as a business partner, communicating that our company would be an effective team player

The road to that success is a story which is worth sharing with those just starting out or looking at ways to enhance their business successes. I welcome the opportunity to speak with those who want to learn about ITI or the road we traveled to become a biotech success story.

Dr. Teri Heiland is the Chief Scientific Officer at Immunomic Therapeutics and cofounder of the Company. She has over 20 years of senior industry leadership experience. Her primary focus and expertise is in DNA vaccine design, optimization and development. In addition to her work to develop, shape and apply the UNITE technology platform, she has led multiple research teams to develop products and platform technologies. Dr. Heiland is also one of the founders of Capital Genomix, Inc. (CGI), a Maryland-based biomarker and drug discovery Company and served as its VP of Research and Development until 2006.

As a key contributor to the Immunomic executive team, Dr. Heiland plays a critical role in forging and achieving leading new research and development collaborations in order to further improve the UNITE platform and develop new applications for the technology. In 2015, those efforts resulted in an exclusive license valued at over $300 million with Japan-based Astellas for next generation allergy vaccines based on the UNITE platform.

Dr. Heiland is an inventor on multiple patents and was a principal investigator on grants from the Department of Defense and NIAID. She received her Ph.D. in Molecular Immunology and Microbiology at the University of Missouri-Columbia.

I am experienced bio-entrepreneur and currently CEO of Immunomic Therapeutics, Inc. (\'ITI\') As primary founder of ITI, I worked with my team to guide the Company through its early stages, selected key strategies for deploying our novel technology and negotiated one of the largest upfront cash license deals in biotechnology ($300 million with Astellas Pharma in allergy).

In order to achieve this success, I needed to draw on all of my career experiences:

- as a scientist with excellent communication skills and depth in immunology and molecular biology

- as the senior leader of my team, getting many moving parts to work towards the same goal together

- as a CEO by assembling highly talented people and enabling them to work unencumbered

- as a business development executive and negotiator

- as a business partner, communicating that our company would be an effective team player

The road to that success is a story which is worth sharing with those just starting out or looking at ways to enhance their business successes. I welcome the opportunity to speak with those who want to learn about ITI or the road we traveled to become a biotech success story.

Eric Winzer joined OpGen as Chief Financial Officer in June 2009. Eric brings almost 30 years of experience in addressing diverse financial issues including raising capital, financial reporting, investor relations, banking, taxation, mergers and acquisitions, financial planning and analysis, and accounting operations. Eric is responsible for all financial functions at the Company. Prior to joining Opgen, Eric served as Executive Vice President and Chief Financial Officer for Avalon Pharmaceuticals, Inc., a biotechnology company developing targeted therapeutics for oncology. Prior to Avalon, Eric was with Life Technologies Corporation (formerly Invitrogen Corporation), a provider of life science technologies for disease research and drug discovery, where he served as Senior VP and Chief Financial Officer, Executive Sponsor for Life’s ERP implementation, and as the VP of Finance. Previously held positions also include Eric’s tenure at Life Technologies Incorporated, where he assumed increasing responsibility as Chief Financial Officer, Secretary and Treasurer, and additionally held various financial positions at Genex Corporation. Currently, Eric serves as director and audit committee chair at Cytomedix, Inc. Eric received his B.A. in Economics and Business Administration from McDaniel College and an M.B.A. from Mount Saint Mary’s University.